Microbix Biosystems Inc. (MBX.TO)
CAD 0.35
(0.0%)
CAD 0.35
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 6.64 Million CAD | 14.11% |
| 2022 | 5.82 Million CAD | -24.71% |
| 2021 | 7.73 Million CAD | 25.27% |
| 2020 | 6.17 Million CAD | -11.66% |
| 2019 | 6.98 Million CAD | 11.67% |
| 2018 | 6.25 Million CAD | -13.98% |
| 2017 | 7.27 Million CAD | -1.33% |
| 2016 | 7.37 Million CAD | 2.52% |
| 2015 | 7.19 Million CAD | 21.52% |
| 2014 | 5.91 Million CAD | 13.2% |
| 2013 | 5.22 Million CAD | -24.41% |
| 2012 | 6.91 Million CAD | 15.41% |
| 2011 | 5.99 Million CAD | -0.12% |
| 2010 | 6 Million CAD | 7.58% |
| 2009 | 5.57 Million CAD | 42.84% |
| 2008 | 3.9 Million CAD | 100.82% |
| 2007 | 1.94 Million CAD | 51.0% |
| 2006 | 1.28 Million CAD | 101.25% |
| 2005 | 639.93 Thousand CAD | 2.88% |
| 2004 | 622.03 Thousand CAD | 45.96% |
| 2003 | 426.15 Thousand CAD | 23.52% |
| 2002 | 345 Thousand CAD | -37.84% |
| 2001 | 555 Thousand CAD | -26.0% |
| 2000 | 750 Thousand CAD | 7.14% |
| 1999 | 700 Thousand CAD | -12.5% |
| 1998 | 800 Thousand CAD | 60.0% |
| 1997 | 500 Thousand CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 6.71 Million CAD | 0.56% |
| 2024 Q3 | 6.35 Million CAD | -5.34% |
| 2024 Q1 | 6.67 Million CAD | 0.49% |
| 2023 FY | 6.64 Million CAD | 14.11% |
| 2023 Q1 | 5.96 Million CAD | 2.46% |
| 2023 Q2 | 6.54 Million CAD | 9.65% |
| 2023 Q4 | 6.64 Million CAD | 1.23% |
| 2023 Q3 | 6.56 Million CAD | 0.33% |
| 2022 Q1 | 6.15 Million CAD | -20.45% |
| 2022 Q4 | 5.82 Million CAD | -0.27% |
| 2022 FY | 5.82 Million CAD | -24.71% |
| 2022 Q2 | 6.35 Million CAD | 3.26% |
| 2022 Q3 | 5.83 Million CAD | -8.1% |
| 2021 Q2 | 6.33 Million CAD | 3.07% |
| 2021 Q3 | 6.33 Million CAD | 0.06% |
| 2021 Q1 | 6.14 Million CAD | -0.51% |
| 2021 FY | 7.73 Million CAD | 25.27% |
| 2021 Q4 | 7.73 Million CAD | 22.09% |
| 2020 Q4 | 6.17 Million CAD | 0.64% |
| 2020 FY | 6.17 Million CAD | -11.66% |
| 2020 Q3 | 6.13 Million CAD | -1.57% |
| 2020 Q2 | 6.23 Million CAD | -15.07% |
| 2020 Q1 | 7.33 Million CAD | 5.01% |
| 2019 FY | 6.98 Million CAD | 11.67% |
| 2019 Q1 | 6.54 Million CAD | 4.54% |
| 2019 Q2 | 6.77 Million CAD | 3.53% |
| 2019 Q4 | 6.98 Million CAD | -1.92% |
| 2019 Q3 | 7.12 Million CAD | 5.19% |
| 2018 Q2 | 6.19 Million CAD | -1.79% |
| 2018 Q4 | 6.25 Million CAD | -2.81% |
| 2018 FY | 6.25 Million CAD | -13.98% |
| 2018 Q1 | 6.31 Million CAD | -13.26% |
| 2018 Q3 | 6.43 Million CAD | 3.9% |
| 2017 FY | 7.27 Million CAD | -1.33% |
| 2017 Q4 | 7.27 Million CAD | 5.61% |
| 2017 Q3 | 6.88 Million CAD | -1.35% |
| 2017 Q2 | 6.98 Million CAD | 3.76% |
| 2017 Q1 | 6.73 Million CAD | -8.73% |
| 2016 Q4 | 7.37 Million CAD | -0.87% |
| 2016 FY | 7.37 Million CAD | 2.52% |
| 2016 Q1 | 7.33 Million CAD | 2.02% |
| 2016 Q2 | 7.43 Million CAD | 1.33% |
| 2016 Q3 | 7.43 Million CAD | 0.04% |
| 2015 Q1 | 6.51 Million CAD | 10.06% |
| 2015 Q3 | 6.61 Million CAD | 1.31% |
| 2015 Q2 | 6.52 Million CAD | 0.24% |
| 2015 FY | 7.19 Million CAD | 21.52% |
| 2015 Q4 | 7.19 Million CAD | 8.73% |
| 2014 Q3 | 6.23 Million CAD | 0.67% |
| 2014 Q4 | 5.91 Million CAD | -5.13% |
| 2014 Q2 | 6.19 Million CAD | 15.51% |
| 2014 FY | 5.91 Million CAD | 13.2% |
| 2014 Q1 | 5.36 Million CAD | 2.61% |
| 2013 Q4 | 5.22 Million CAD | -25.32% |
| 2013 Q1 | 6.87 Million CAD | -0.57% |
| 2013 FY | 5.22 Million CAD | -24.41% |
| 2013 Q2 | 7.03 Million CAD | 2.3% |
| 2013 Q3 | 7 Million CAD | -0.5% |
| 2012 Q4 | 6.91 Million CAD | 14.81% |
| 2012 FY | 6.91 Million CAD | 15.41% |
| 2012 Q3 | 6.02 Million CAD | -1.44% |
| 2012 Q2 | 6.11 Million CAD | 0.4% |
| 2012 Q1 | 6.08 Million CAD | 1.59% |
| 2011 Q1 | 5.76 Million CAD | -3.97% |
| 2011 FY | 5.99 Million CAD | -0.12% |
| 2011 Q4 | 5.99 Million CAD | -5.08% |
| 2011 Q3 | 6.31 Million CAD | 0.37% |
| 2011 Q2 | 6.29 Million CAD | 9.16% |
| 2010 FY | 6 Million CAD | 7.58% |
| 2010 Q4 | 6 Million CAD | 4.91% |
| 2010 Q2 | 5.7 Million CAD | 0.53% |
| 2010 Q3 | 5.72 Million CAD | 0.27% |
| 2010 Q1 | 5.67 Million CAD | 1.73% |
| 2009 Q3 | 5.48 Million CAD | 6.23% |
| 2009 Q4 | 5.57 Million CAD | 1.69% |
| 2009 Q1 | 3.92 Million CAD | 0.58% |
| 2009 FY | 5.57 Million CAD | 42.84% |
| 2009 Q2 | 5.16 Million CAD | 31.46% |
| 2008 Q4 | 3.9 Million CAD | 13.96% |
| 2008 Q2 | 1.92 Million CAD | -0.33% |
| 2008 Q1 | 1.93 Million CAD | -0.63% |
| 2008 FY | 3.9 Million CAD | 100.82% |
| 2008 Q3 | 3.42 Million CAD | 77.93% |
| 2007 Q4 | 1.94 Million CAD | 2.9% |
| 2007 Q1 | 1.61 Million CAD | 25.38% |
| 2007 FY | 1.94 Million CAD | 51.0% |
| 2007 Q2 | 1.9 Million CAD | 17.78% |
| 2007 Q3 | 1.88 Million CAD | -0.63% |
| 2006 FY | 1.28 Million CAD | 101.25% |
| 2006 Q4 | 1.28 Million CAD | 8.47% |
| 2006 Q3 | 1.18 Million CAD | 0.21% |
| 2006 Q2 | 1.18 Million CAD | 48.14% |
| 2006 Q1 | 799.77 Thousand CAD | 24.98% |
| 2005 Q4 | 639.93 Thousand CAD | 9.56% |
| 2005 Q3 | 584.07 Thousand CAD | 1.49% |
| 2005 Q2 | 575.49 Thousand CAD | -2.84% |
| 2005 Q1 | 592.32 Thousand CAD | -4.78% |
| 2005 FY | 639.93 Thousand CAD | 2.88% |
| 2004 Q4 | 622.03 Thousand CAD | -2.75% |
| 2004 FY | 622.03 Thousand CAD | 45.96% |
| 2004 Q1 | 392.22 Thousand CAD | -7.96% |
| 2004 Q2 | 632.56 Thousand CAD | 61.28% |
| 2004 Q3 | 639.62 Thousand CAD | 1.12% |
| 2003 Q2 | 650 Thousand CAD | -1.89% |
| 2003 Q4 | 426.15 Thousand CAD | -33.15% |
| 2003 Q3 | 637.5 Thousand CAD | -1.92% |
| 2003 FY | 426.15 Thousand CAD | 23.52% |
| 2003 Q1 | 662.5 Thousand CAD | 92.03% |
| 2002 Q1 | 527.5 Thousand CAD | -4.95% |
| 2002 FY | 345 Thousand CAD | -37.84% |
| 2002 Q2 | 500 Thousand CAD | -5.21% |
| 2002 Q3 | 447.5 Thousand CAD | -10.5% |
| 2002 Q4 | 345 Thousand CAD | -22.91% |
| 2001 FY | 555 Thousand CAD | -26.0% |
| 2001 Q4 | 555 Thousand CAD | -8.65% |
| 2001 Q3 | 607.58 Thousand CAD | -7.95% |
| 2001 Q2 | 660.08 Thousand CAD | -7.36% |
| 2001 Q1 | 712.5 Thousand CAD | -5.0% |
| 2000 Q3 | 800 Thousand CAD | -11.11% |
| 2000 Q2 | 900 Thousand CAD | 50.0% |
| 2000 Q1 | 600 Thousand CAD | -14.29% |
| 2000 FY | 750 Thousand CAD | 7.14% |
| 2000 Q4 | 750 Thousand CAD | -6.25% |
| 1999 Q1 | 700 Thousand CAD | -12.5% |
| 1999 Q3 | 700 Thousand CAD | 0.0% |
| 1999 Q2 | 700 Thousand CAD | 0.0% |
| 1999 Q4 | 700 Thousand CAD | 0.0% |
| 1999 FY | 700 Thousand CAD | -12.5% |
| 1998 Q2 | 500 Thousand CAD | 25.0% |
| 1998 Q1 | 400 Thousand CAD | -20.0% |
| 1998 FY | 800 Thousand CAD | 60.0% |
| 1998 Q4 | 800 Thousand CAD | 0.0% |
| 1998 Q3 | - CAD | -100.0% |
| 1997 Q2 | 600 Thousand CAD | 20.0% |
| 1997 Q3 | 500 Thousand CAD | -16.67% |
| 1997 Q4 | 500 Thousand CAD | 0.0% |
| 1997 Q1 | 500 Thousand CAD | 0.0% |
| 1997 FY | 500 Thousand CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Appili Therapeutics Inc. | 8.18 Million CAD | 18.81% |
| Eupraxia Pharmaceuticals Inc. | 13.78 Million CAD | 51.783% |
| Helix BioPharma Corp. | - CAD | -Infinity% |
| Medicenna Therapeutics Corp. | - CAD | -Infinity% |
| Satellos Bioscience Inc. | - CAD | -Infinity% |
| Oncolytics Biotech Inc. | 423 Thousand CAD | -1470.999% |
| Sernova Corp. | 136.12 Thousand CAD | -4781.853% |